Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | HTR3A | P46098 | 2/20 | 0.53 |
| ▸ | ACACB | O00763 | 1/20 | 0.45 |
| ▸ | ACACA | Q13085 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1996700 | 0.87 | KDM4E (0.66) | KMT2AKDM4EALDH1A1MEN1USP2 | |
| SCHEMBL1996892 | 0.82 | HTR3A (0.62) | KMT2AKDM4EALDH1A1MEN1USP2 | |
| SCHEMBL5910624 | 0.79 | KMT2A (0.69) | KMT2AKDM4EALDH1A1MEN1USP2 | |
| SCHEMBL989988 | 0.76 | HTR3A (0.39) | HTR3A | |
| SCHEMBL28455263 | 0.74 | KDM4E (0.75) | KMT2AKDM4EALDH1A1MEN1USP2 | |
| SCHEMBL991290 | 0.73 | CYP1A2 (0.40) | KDM4EALDH1A1HTR3AMAPT | |
| SCHEMBL28538954 | 0.73 | KDM4E (0.98) | KMT2AKDM4EALDH1A1MEN1USP2 | |
| SCHEMBL990733 | 0.72 | WNT1 (0.46) | KDM4EALDH1A1 | |
| SCHEMBL19989884 | 0.72 | CKS1B (0.55) | KMT2AKDM4EALDH1A1MEN1USP2 | |
| SCHEMBL5910282 | 0.71 | KMT2A (1.00) | KMT2AKDM4EALDH1A1MEN1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | TPMT, TSLP, THPO | KMT2A 3648/4885KDM4E 3351/4885ALDH1A1 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.